← All trials
NCT05818137
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2023
- Primary completion
- Mar 11, 2024
- Completion date
- Aug 13, 2025
- First posted
- Apr 18, 2023
- Last posted
- Oct 12, 2023
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.